Pulmatrix (PULM) Stock Price, News & Analysis

Company Overview

Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates. The company was founded in 2003 and is headquartered in Bedford, Massachusetts.

Key Stats

• Today's Range: $7.33 to $8.71
• 50-Day Range: $5.39 to $9.09
• 52-Week Range: $1.78 to $10.40
• Volume: 108,940 shs
• Average Volume: 134,924 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

PULM Stock Analysis - Frequently Asked Questions

How have PULM shares performed this year?

Pulmatrix's stock was trading at $6.98 at the beginning of 2025. Since then, PULM shares have increased by 6.4% and is now trading at $7.43.
View the best growth stocks for 2025 here.

How were Pulmatrix's earnings last quarter?

Pulmatrix, Inc. (NASDAQ:PULM) announced its quarterly earnings data on Thursday, May, 15th. The biotechnology company reported ($0.50) earnings per share (EPS) for the quarter. Pulmatrix had a negative net margin of 122.46% and a negative trailing twelve-month return on equity of 94.97%.

When did Pulmatrix's stock split?

Pulmatrix's stock reverse split on the morning of Tuesday, March 1st 2022. The 1-20 reverse split was announced on Tuesday, March 1st 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, March 1st 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Who are Pulmatrix's major shareholders?

Pulmatrix's top institutional shareholders include SBI Securities Co. Ltd. (1.43%).
View institutional ownership trends.

How do I buy shares of Pulmatrix?

Shares of PULM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Pulmatrix own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Pulmatrix investors own include NVIDIA (NVDA), CymaBay Therapeutics (CBAY), GE Aerospace (GE), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO) and Adobe (ADBE).

Company Calendar

• Last Earnings: 5/15/2025
• Today: 6/22/2025
• Next Earnings (Estimated): 8/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:PULM
• CIK: 1574235
• Web: www.pulmatrix.com
• Phone: (781) 357-2333
• Fax: 707-525-9906
• Employees: 20
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($3.34)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$6.94 million
• Net Margins: -122.46%
• Pretax Margin: -498.39%
• Return on Equity: -94.97%
• Return on Assets: -84.57%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 8.90
• Quick Ratio: 8.90

Sales & Book Value

• Annual Sales: $7.81 million
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.45 per share
• Price / Book: 3.03

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: 1.44